Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity

Wang,Ya‑Di; Chen,Su‑Xian; Ren,Li‑Qun

doi:10.3892/ol.2016.4424

Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity

Authors:
- Ya‑Di Wang
- Su‑Xian Chen
- Li‑Qun Ren
View Affiliations

Affiliations: Department of Experimental Pharmacology and Toxicology, School of Pharmacy, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Pathology, The Third Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121000, P.R. China
Published online on: April 7, 2016 https://doi.org/10.3892/ol.2016.4424
Pages: 3483-3492

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Observational and experimental studies have produced inconsistent evidence about the association of serum levels of B-type natriuretic peptide (BNP) with anthracycline-induced cardiotoxicity (AIC). Therefore, the current meta‑analysis examined the association between serum BNP levels and AIC by using data from high quality studies published in peer‑reviewed journals. Relevant studies were identified through literature searches of China National Knowledge Infrastructure (CNKI), Web of Science, PubMed, Google Scolar and China BioMedicine (CBM). STATA software was used in this meta‑analysis for statistical analysis. In addition, the crude standardized mean difference (SMD) with 95% confidence interval (CI) for the highest vs. the lowest category of serum BNP levels was calculated. A total of 8 independent case‑control studies, containing 126 AIC patients and 569 healthy controls, were included for the current meta‑analysis. The results indicated a significant difference in serum BNP levels between the cardiotoxic group and normal group, with respect to post‑treatment and pretreatment with anthracyclines. Specifically, the serum levels of BNP increased remarkably after treatment with anthracyclines in the cardiotoxic group, compared with the normal group. No publication bias was detected in this meta-analysis. The findings of the present study provide strong evidence that serum BNP levels may be associated with AIC.

View Figures

View References

1	Lee HS, Son CB, Shin SH and Kim YS: Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity. Cancer Res Treat. 40:121–126. 2008. View Article : Google Scholar : PubMed/NCBI
2	Aapro M, Bernard-Marty C, Brain EG, Batist G, Erdkamp F, Krzemieniecki K, Leonard R, Lluch A, Monfardini S, Ryberg M, et al: Anthracycline cardiotoxicity in the elderly cancer patient: A SIOG expert position paper. Ann Oncol. 22:257–267. 2011. View Article : Google Scholar : PubMed/NCBI
3	Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, et al: Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 30:1422–1428. 2012. View Article : Google Scholar : PubMed/NCBI
4	Lipshultz SE, Alvarez JA and Scully RE: Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 94:525–533. 2008. View Article : Google Scholar : PubMed/NCBI
5	Ewer MS and Lenihan DJ: Left ventricular ejection fraction and cardiotoxicity: Is our ear really to the ground? J Clin Oncol. 26:1201–1203. 2008. View Article : Google Scholar : PubMed/NCBI
6	van der Pal HJ, van Dalen EC, Hauptmann M, Kok WE, Caron HN, van den Bos C, Oldenburger F, Koning CC, van Leeuwen FE and Kremer LC: Cardiac function in 5-year survivors of childhood cancer: A long-term follow-up study. Arch Intern Med. 170:1247–1255. 2010. View Article : Google Scholar : PubMed/NCBI
7	Kremer LC, van der Pal HJ, Offringa M, van Dalen EC and Voûte PA: Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: A systematic review. Ann Oncol. 13:819–829. 2002. View Article : Google Scholar : PubMed/NCBI
8	Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, Albrile F, Bobbio M and Merlano M: Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: Effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol. 148:194–198. 2011. View Article : Google Scholar : PubMed/NCBI
9	Pongprot Y, Sittiwangkul R, Charoenkwan P and Silvilairat S: Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer. J Pediatr Hematol Oncol. 34:589–595. 2012. View Article : Google Scholar : PubMed/NCBI
10	Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M and Sakurai M: Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 37:4–9. 2001. View Article : Google Scholar : PubMed/NCBI
11	Skovgaard D, Hasbak P and Kjaer A: BNP predicts chemotherapy-related cardiotoxicity and death: Comparison with gated equilibrium radionuclide ventriculography. PLoS One. 9:e967362014. View Article : Google Scholar : PubMed/NCBI
12	Beleigoli AM, Boersma E, de Diniz MF, Vidigal PG, Lima-Costa MF and Ribeiro AL: C-reactive protein and B-type natriuretic peptide yield either a non-significant or a modest incremental value to traditional risk factors in predicting long-term overall mortality in older adults. PLoS One. 8:e758092013. View Article : Google Scholar : PubMed/NCBI
13	Khalaf MA, Abdelrahman TM and Abbas MF: Values of using QTc and N-terminal fragment of B-type natriuretic peptide as markers for early detection of acute antipsychotic drugs-induced cardiotoxicity. Cardiovasc Toxicol. 11:10–17. 2011. View Article : Google Scholar : PubMed/NCBI
14	Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, et al: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 347:161–167. 2002. View Article : Google Scholar : PubMed/NCBI
15	Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG and Richards AM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 355:1126–1130. 2000. View Article : Google Scholar : PubMed/NCBI
16	Geske JB, McKie PM, Ommen SR and Sorajja P: B-type natriuretic peptide and survival in hypertrophic cardiomyopathy. J Am Coll Cardiol. 61:2456–2460. 2013. View Article : Google Scholar : PubMed/NCBI
17	Gerber IL, Stewart RA, Legget ME, West TM, French RL, Sutton TM, Yandle TG, French JK, Richards AM and White HD: Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation. 107:1884–1890. 2003. View Article : Google Scholar : PubMed/NCBI
18	Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, Di Battiste PM, McCabe CH, Gibson CM, Cannon CP and Braunwald E: Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 41:1264–1272. 2003. View Article : Google Scholar : PubMed/NCBI
19	Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B and Pacher R: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 105:2392–2397. 2002. View Article : Google Scholar : PubMed/NCBI
20	Daniels LB and Maisel AS: Natriuretic peptides. J Am Coll Cardiol. 50:2357–2368. 2007. View Article : Google Scholar : PubMed/NCBI
21	Costa VN, Nomura RM, Miyadahira S, Vieira Francisco RP and Zugaib M: Cord blood B-type natriuretic peptide levels in placental insufficiency: Correlation with fetal Doppler and pH at birth. Eur J Obstet Gynecol Reprod Biol. 171:231–234. 2013. View Article : Google Scholar : PubMed/NCBI
22	Esteves WA, Lodi-Junqueira L, Neto CP, Tan TC, Nascimento BR, Mehrotra P, Barbosa MM, Ribeiro AL and Nunes MC: The impact of right ventricular stroke work on B-type natriuretic peptide levels in patients with mitral stenosis undergoing percutaneous mitral valvuloplasty. J Interv Cardiol. 26:501–508. 2013.PubMed/NCBI
23	Jan SL, Lin SJ, Fu YC, Lin MC, Chan SC and Hwang B: Plasma B-type natriuretic peptide study in children with severe enterovirus 71 infection: A pilot study. Int J Infect Dis. 17:e1166–e1171. 2013. View Article : Google Scholar : PubMed/NCBI
24	Vila G, Resl M, Stelzeneder D, Struck J, Maier C, Riedl M, Hülsmann M, Pacher R, Luger A and Clodi M: Plasma NT-proBNP increases in response to LPS administration in healthy men. J Appl Physiol (1985). 105:1741–1745. 2008. View Article : Google Scholar : PubMed/NCBI
25	Clerico A, Giannoni A, Vittorini S and Passino C: Thirty years of the heart as an endocrine organ: Physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol. 301:H12–H20. 2011. View Article : Google Scholar : PubMed/NCBI
26	Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, Dumontet C, Thieblemont C, Arnaud P, Antal D, et al: Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 22:1864–1871. 2004. View Article : Google Scholar : PubMed/NCBI
27	Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
28	Zintzaras E and Ioannidis JP: HEGESMA: Genome search meta-analysis and heterogeneity testing. Bioinformatics. 21:3672–3673. 2005. View Article : Google Scholar : PubMed/NCBI
29	Zintzaras E and Ioannidis JP: Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 28:123–137. 2005. View Article : Google Scholar : PubMed/NCBI
30	Higgins JP and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002. View Article : Google Scholar : PubMed/NCBI
31	Song F and Gilbody S: Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis. BMJ. 316:4711998.PubMed/NCBI
32	Peters JL, Sutton AJ, Jones DR, Abrams KR and Rushton L: Comparison of two methods to detect publication bias in meta-analysis. JAMA. 295:676–680. 2006. View Article : Google Scholar : PubMed/NCBI
33	Aggarwal S, Pettersen MD, Bhambhani K, Gurczynski J, Thomas R and L'Ecuyer T: B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer. 49:812–816. 2007. View Article : Google Scholar : PubMed/NCBI
34	Zhang SJ and Cui YZ: Measurement of brain natriuretic peptide ring based chemotherapy in patients with cardiac toxicity in anthracene. Chinese Journal of Difficult and Complicated Cases. 10:444–445. 2011.
35	Cao S, Pang DM, Duan HB, Lin YD and Li LT: Application value in the levels of plasma NTproBNP in patients with cardiac toxicity. Modern Diagnosis & Treatment. 303–304. 2013.
36	Mavinkurve-Groothuis AM, Marcus KA, Pourier M, Loonen J, Feuth T, Hoogerbrugge PM, de Korte CL and Kapusta L: Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): A prospective study. Eur Heart J Cardiovasc Imaging. 14:562–569. 2013. View Article : Google Scholar : PubMed/NCBI
37	Krawczuk-Rybak M, Dakowicz L, Hryniewicz A, Maksymiuk A, Zelazowska-Rutkowska B and Wysocka J: Cardiac function in survivors of acute lymphoblastic leukaemia and Hodgkin's lymphoma. J Paediatr Child Health. 47:455–459. 2011. View Article : Google Scholar : PubMed/NCBI